CJC-1295

From WikiMD.org
Jump to navigation Jump to search

CJC-1295

CJC-1295 (/siːdʒeɪsiː/ /wʌn/ /tuː/ /naɪn/ /faɪv/) is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue made up of 30 amino acids. It has been found to be effective in increasing growth hormone and IGF-1 levels, and its benefits include longer binding time to the Growth Hormone Receptor which results in an overall increase in growth hormone.

Etymology

The term "CJC-1295" is derived from the initials of the ConjuChem Biotechnologies company that first synthesized this peptide, with "1295" being an arbitrary sequence number.

Usage

CJC-1295 is typically provided in vials containing 2 or 5 mg of lyophylized powder, though the amount can vary. The contents should be reconstituted by adding a convenient amount of sterile or bacteriostatic water. If for example 2 mL is chosen and the dosing of the vial is 2 mg, the resulting solution then has a concentration of 1 mg/mL, or 1000 mcg/mL.

Side Effects

As with any peptide, there are potential side effects from using CJC-1295. These can include: mild irritation at the injection site, flushing, headache and dizziness. These side effects are typically mild and subside quickly. More serious side effects can include: an allergic reaction (hives, difficulty breathing, swelling of the face, lips, tongue, or throat), chest pain, dark urine, and irregular heartbeat.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski